HQL offers a 14.2% dividend yield and diverse exposure to healthcare and life science companies. Since abrdn's acquisition in 2023, HQL has delivered a total return of 25.5%, though its price ...
HQL offers a high 12% yield and trades at a discount, making it attractive for income-focused investors seeking healthcare sector exposure. The fund is heavily weighted in biotechnology, leading to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback